Company intelligence / Profile preview
Humedix
Seongnam-si, Gyeonggi-do, South Koreahumedix.com ↗
- Ownership
- Private
- Development stage
- Commercial
01
Overview
Humedix has a broad commercial portfolio in hyaluronic acid-based fillers, arthritis injectables, botulinum toxin type A (“Riztox”), PDRN-based regenerative therapies (“Livitalex”), medical devices (“Derma Shine”), and functional cosmetics. Its lead pipeline pharmaceutical program—GB‑5001 long‑acting donepezil injection—is in Phase 1 clinical trials targeting Alzheimer’s disease.
- Therapeutic areas
- DermatologyRheumatologyImmunologyNeurology
- Modalities
- Small moleculeBiologicBotulinum toxinPolymer-drug conjugate therapyMedical deviceCosmetic product formulations
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Partnerships
G2GBio (platform/licensing partner on GB–5001)Korea Pharma Co.global biotechnology companies
Beyond the preview
Go deeper on Humedix.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Humedix.